Antibiotic resistance is widespread. Its global human and economic burden is tremendous and constantly increasing. Despite the recognised and growing need for new antibiotics, most large pharmaceutical companies today have dropped antibacterial drug discovery programmes.
Sarstedt – Pipette Tips
ProductsSarstedt offers an extensive range of certified and geometrically optimised pipette tips with and without filters for all common pipettes.
Tecan’s Spark 20M multimode microplate reader
ProductsTailor-made solutions to suit virtually any drug discovery or advanced life science research application.
His Mag Sepharose Ni
ProductsDesigned for efficient, small-scale purification and screening of histidine-tagged proteins from different sources.
InMotion Flex Autosampler
ProductsFlexible automation efficient titrations – Increase testing throughput in your lab with the single row InMotion Flex Autosampler.
Biotech in agriculture lives another day
OpinionPeople do plenty of moaning about the European Parliament, so lets look at something good that it did in October, when it rejected an EC proposal for national GMO bans.
The Simple Western
ProductsGel-free. Blot-free. Hands-free. A Simple Western is the Western you know well, only simplified.
Make innovation in healthcare happen
OpinionEuropean citizens are living longer than ever before and this trend is further continuing due to unprecedented medical advances and improved standards of living. By 2020, more than a quarter of Europeans will be over the age of 60.
Genetically modified decisions
OpinionA little bird tells me that the European Commission is moving towards a decision on whether various technologies involved in development of novel plant strains will fall under the terms of current GMO legislation.
Biometra TAdvanced
ProductsThe new generation Biometra thermal cycler – the high-performance thermal cycler for DNA amplification by PCR.
Antibiotics: Novel business models needed
OpinionAntibiotic resistance is widespread. Its global human and economic burden is tremendous and constantly increasing. Despite the recognised and growing need for new antibiotics, most large pharmaceutical companies today have dropped antibacterial drug discovery programmes.